MRZM - Marizyme, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Marizyme, Inc.

555 Heritage Drive
Suite 205
Jupiter, FL 33458
United States
(561) 935-9955

Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Mr. David L. Barthel M.B.A.CEO, Sec. & Director350kN/A1959
Dr. Catherine J. Pachuk Ph.D.Exec. VP & Chief Scientific Officer325kN/A1957
Dr. Steven Scott Brooks FACC, M.B.A., M.D.Exec. VP of Medical & Regulatory Affairs and Chief Medical Officer300kN/A1970
Mr. George Kovalyov C.A., CPACFO & TreasurerN/AN/A1985
Dr. Claudio Rigatto M.D.Chief Medical Officer of My Health LogicN/AN/AN/A
Kari JacobsonControllerN/AN/AN/A
Mr. Harrison Albert Ross C.F.A.VP of Fin.N/AN/A1993
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Marizyme, Inc., a multi-technology biomedical company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform for treating chronic wounds and burns, thrombosis, and dissolving plaque and biofilms on teeth. In addition, it focuses on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries, and other indications. Further, it is involved in developing MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform for chronic kidney disease assessment; and MAR-FG-001, a fat grafting technology for use in fat grafting procedures. The company was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida.

Corporate Governance

Marizyme, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.